Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
Self-apposing Stentys Stents Registry
Self-apposing, drug-eluting Stentys coronary stents represent a valuable tool for the treatment of coronary artery stenosis. Their ability to adapt to widely varying vessel calibers and to auto-expand after their release to…
- Trial name
- SPARTA (NCT02784405)
- Where
- 14 sites in Italy, Malaysia and 1 more
- Volunteers
- 100 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE ONYX China Single Arm Study
It is a single arm clinical evaluation of safety and efficacy of the Medtronic Resolute Onyx™ zotarolimus-eluting coronary stent system in subjects who are eligible for percutaneous transluminal coronary angioplasty (PTCA) in de…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03471845
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Medtronic Vascular
Heart Disease, Brain Vascular Accident
A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease
The primary objective of this study is to assess the safety and effectiveness of stenting in the treatment of obstructive carotid artery disease.
- Conditions
- Heart Disease, Brain Vascular Accident, Carotid Artery Disease, Carotid Stenosis
- Trial name
- NCT00178672
- Testing
- Angioguard XP distal protection device, Heart Catheterization -Angioplasty, stenting
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- The University of Texas Health Science Center, Houston
Coronary Artery Disease
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
This study is a prospective, multi-center single arm registry trial, planning to enroll 785 subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year after index procedure.
- Trial name
- NCT04179045
- Testing
- The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Where
- 5 sites in China
- Volunteers
- 785 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Coronary Artery Disease
Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "Real-World" Practice
PANDA III is sought to investigate the safety and efficacy of a PLGA-polymer with electro-grafting base layer sirolimus-eluting stent (SES) versus a PLA-polymer SES at 12 months follow-up.
- Trial name
- PANDA-III (NCT02017275)
- Testing
- BuMA, EXCEL
- Where
- China
- Volunteers
- 2,348 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease
Catheter-Based Treatment of Cardiovascular Disease
This study offers catheter-based treatment of heart or artery disease. This protocol permits treatment of patients with cardiovascular diseases who may not be eligible to participate in current research protocols.
- Conditions
- Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease, Structural Heart Disease
- Trial name
- NCT00380016
- Testing
- Percutaneous Transluminal Angioplasty
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Safety Issues, Efficacy, Self
The Lower Silesia Shockwave Registry
Lower Silesia Shockwave Registry (LSSR), is a observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of shockwave intravascular lithotripsy in two…
- Trial name
- LSSR (NCT05916898)
- Testing
- PCI with support of Shockwave Intravascular Lithotripsy
- Where
- 2 sites in Poland
- Volunteers
- 400 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
Coronary Artery Disease
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation
Objective of this First in Man study is to assess feasibility and safety of Qvanteq's bioactive coronary stent for treatment of stable coronary artery disease patients with de novo coronary artery stenosis in native vessels.
- Trial name
- NCT02176265
- Testing
- Qvanteq bioactive coronary stent
- Where
- 6 sites in Netherlands, Switzerland
- Volunteers
- 31 people
- Sponsor
- Qvanteq AG
Coronary Artery Disease
Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)
The purpose of this study is to compare the safety and effectiveness of drug-eluting stent implantation compared to optimal medical treatment in patients with chronic total occlusion.
- Trial name
- NCT01078051
- Testing
- Cypher, xience, Endeavor, Taxus, optimal medical therapy
- Where
- 26 sites in India, Indonesia and 3 more
- Volunteers
- 840 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Use of a Point-of-Care Platelet Function Assay for the Prediction of Atherothrombotic Events
1. To evaluate the role of VerifyNow test as prognostic marker in routine clinical practice using drug-eluting stents. 2. To determine the add-on-effect of VerifyNow test beyond on conventional risk factors (clinical, lesions, or…
- Trial name
- ASAN-VERIFY (NCT01183754)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- CardioVascular Research Foundation, Korea
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Coronary Artery Disease, Coronary Atherosclerosis
Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems
The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for…
- Trial name
- ELITE (NCT00715884)
- Testing
- CYPHER® ELITE™ Sirolimus-Eluting Stent System, CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
- Where
- United States
- Volunteers
- 678 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
The Nordic-Baltic Bifurcation Study IV
How should coronary artery stenoses with significant side branch be stented? A strategy of stenting both main vessel and side branch compared to a strategy of stenting the main vessel and only stenting the side branch if…
- Trial name
- BIF IV (NCT01496638)
- Testing
- Implantation of coronary stent in bifurcation lesion
- Where
- Denmark
- Volunteers
- 450 people
- Sponsor
- Evald Hoej Christiansen
Coronary Artery Disease
Long-term Comparison of Stenting Versus Off-pump Coronary Bypass Surgery
The randomized comparison of two strategies in coronary revascularization: bypass surgery without the use of a heart lung machine and coronary stenting procedure.
- Trial name
- OCTOSTENT (NCT00975858)
- Testing
- Coronary Revascularization
- Where
- Netherlands
- Volunteers
- 280 people
- Sponsor
- UMC Utrecht
In-Stent Restenosis, Coronary Artery Disease
VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI
This multicenter observational study investigates whether lipid and lipoprotein subfractions measured by Vertical Auto Profile (VAP) are associated with coronary in-stent restenosis after percutaneous coronary intervention (PCI).
- Trial name
- NCT07533656
- Testing
- No intervention
- Where
- China
- Volunteers
- 3,600 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Disease
The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.
The main objective of this study is to assess the effectiveness of the CYPHER™ (sirolimus-eluting) stent in reducing in-lesion late lumen loss in de novo native coronary artery lesions in small vessels (2.25 - 2.75 mm) as…
- Trial name
- SVELTE (NCT00235066)
- Testing
- PCI
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease, Cardiovascular Diseases
Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent
The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the "real world" daily practice as compared with the other drug-eluting stents.
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Heart Diseases, Myocardial Ischemia
- Trial name
- IRIS SynergyXD (NCT05044273)
- Testing
- Synergy XD stent or Synergy Megatron™ Stent
- Where
- 23 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Jung-min Ahn
Coronary Artery Disease
LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)
This is a multi-center, randomized, study to compare the efficacy of zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime or Xience Xpedition or Xience Alpine stent) for…
- Trial name
- NCT01489761
- Testing
- percutaneous coronary intervention
- Where
- 11 sites in South Korea
- Volunteers
- 302 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Virtue® SAB in the Treatment of Coronary ISR Trial
A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the…
- Trial name
- NCT07045194
- Testing
- Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon
- Where
- 22 sites in United States
- Volunteers
- 740 people
- Sponsor
- Orchestra BioMed, Inc
Coronary Artery Disease
The Intra-Drug Eluting Stent (DES) Restenosis Study
A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.
- Trial name
- CRISTAL (NCT00323895)
- Testing
- drug-eluting stent and balloon angioplasty, drug-eluting stent
- Where
- 2 sites in France
- Volunteers
- 320 people
- Sponsor
- Cordis US Corp.